Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer
- 20 October 2010
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (30), 4562-4567
- https://doi.org/10.1200/jco.2010.30.7025
Abstract
Purpose To assess whether the low incidence of severe neutropenia in castrated men with prostate cancer treated with docetaxel is the result of changes in systemic clearance. Patients and Methods A...Keywords
This publication has 34 references indexed in Scilit:
- Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate CancerJournal of Clinical Oncology, 2008
- Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity MeasurementsClinical Pharmacology & Therapeutics, 2008
- Docetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 2006
- Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxelCancer Biology & Therapy, 2005
- DIFFERENT IN VITRO METABOLISM OF PACLITAXEL AND DOCETAXEL IN HUMANS, RATS, PIGS, AND MINIPIGSDrug Metabolism and Disposition, 2004
- Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemiaBlood, 2004
- Differential Gene Expression of Organic Anion Transporters in Male and Female RatsBiochemical and Biophysical Research Communications, 2002
- Isolation of a Family of Organic Anion Transporters from Human Liver and KidneyBiochemical and Biophysical Research Communications, 2001
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 1999